Table 2.

All-grade and grade ≥3 treatment-related adverse events occurring in at least 2 patients (21/7 and CDD capsule regimens, n = 69)

Adverse eventAll grades, n (%)Grade ≥ 3, n (%)
Patients with at least one AE44 (63.8)9 (13)
Constitutional
 Fatigue6 (8.7)0
 Asthenia5 (7.2)0
 Peripheral edema3 (4.3)1 (1.4)
 Pyrexia2 (2.9)0
 Decreased appetite8 (11.6)0
 Weight loss2 (2.9)0
Dermatologic
 Rash-related skin toxicitiesa18 (26.1)5 (7.2)
 Dry skin5 (7.2)0
 Pruritus5 (7.2)0
Gastrointestinal
 Nausea15 (21.7)0
 Diarrhea14 (20.3)2 (2.9)
 Vomiting7 (10.1)0
 Constipation4 (5.8)0
 Dry mouth3 (4.3)0
Hematologic
 Anemia2 (2.9)0
 Eosinophilia2 (2.9)0
Metabolic/Biochemical
 Hyperglycemia5 (7.2)0
 Hypomagnesemia3 (4.3)0
Musculoskeletal
 Muscle spasms2 (2.9)0
Neurologic
 Dizziness2 (2.9)0
 Headache2 (2.9)0
Vascular
 Hypotension3 (4.3)0
Visual/Eye disorders
 Visual impairmentb2 (2.9)0
  • aIncludes events coded as rash, macular rash, follicular rash, generalized rash, erythema, skin exfoliation, photosensitivity, eczema, and fissuring.

  • bIncludes one event of chromatopsia and one self-limited event of visual disturbance.